Epidemiology and Treatment of Eosinophilic Fasciitis: An Analysis of 63 Patients From 3 Tertiary Care Centers
Eosinophilic fasciitis (EF) is a rare fibrosing disorder of the fascia characterized by erythema, edema, and induration of the bilateral extremities. Joint contractures and related functional limitation commonly occur owing to fascial involvement overlying the joints. Hematologic abnormalities, including peripheral eosinophilia and monoclonal gammopathy, may occur. Systemic corticosteroids are considered first-line therapy; however, prolonged treatment is frequently required in patients with EF, and a standardized therapeutic pro-tocol is lacking. 1, 2 Given the dearth of systematic data guiding treatment, we evaluated the presentation and clinical response of EF in 63 patients at 3 tertiary care centers.
Methods | After institutional review board approval from Partners HealthCare and New York University Langone Medical Center, we performed a search of the Partners Research Patient Data Registry (January 1, 1995-May 31, 2015; Brigham and Women's and Massachusetts General Hospitals) and 2 medical record databases at New York University Langone Medical Center (January 1, 2005-May 31, 2015), which together include more than 20 million patient visits. The search was based on the term fasciitis and EF-related International Classification of Diseases, Ninth Revision codes (728.89, 728.9, and 729.4). Data were extracted on patient demographics, disease presentation, treatment, and clinical response, defined as complete response (resolution of erythema and/or edema with no or minimal persistent induration), partial response (incomplete improvement of erythema, edema, and/or induration), or no response (lack of improvement). Each patient record, along with clinical photographs when available, was reviewed to ensure accurate diagnosis of EF. The 2 senior authors (A.N.F. and R.A.V.) independently confirmed the diagnosis of EF and assessment of clinical response. Categorical variables were compared using 2-tailed χ 2 tests, with P ≤ .05 considered statistically significant. Analysis was conducted from October 1, 2014, to May 31, 2015.
Results | Of 1626 patients with fasciitis identified, 63 had confirmed EF ( Table 1 ). Mean (SD) time from onset of EF to diagnosis was 11 (8) months. Seventy-nine percent of patients (37 of 47) were initially misdiagnosed, most frequently with systemic sclerosis (SSc), deep vein thrombosis, hypereosinophilic syndrome, or cellulitis. Most patients who were misdiagnosed with SSc underwent unnecessary evaluation for internal disease and failed to receive corticosteroids before the correct diagnosis. Four patients who were misdiagnosed with hypereosinophilic syndrome or eosinophilic leukemia underwent bone marrow biopsies and 1 patient received chemotherapy. Fifty percent of patients (31 of 62) had joint contractures, yet only 37% (23 of 62) were referred for physical therapy. In 28% of patients (8 of 29), trauma or intense exercise preceded the onset of EF. During a mean (SD) follow-up of 39 (43) months, complete response was more likely with the combination of corticosteroids and methotrexate (21 of 33 patients [64%]) compared with other treatment combinations (9 of 31 [29%]; P = .006), corticosteroid monotherapy (10 of 33 [30%]; P = .007), or treatment without corticosteroids (1 of 6 [17%]; P = .03) ( Table 2 ). Complete response also occurred more frequently in patients diagnosed within 6 months of the onset of EF, but this finding was not statistically significant (10 of 15 [67%] vs 17 of 31 [55%]; P = .45).
Discussion | To our knowledge, this study represents the largest cohort to date of patients with EF and underscores the diagnostic and therapeutic challenge that EF presents. Frequent misdiagnoses likely accounted for the mean diagnostic delay of almost 1 year and resulted in unnecessary, invasive procedures and inappropriate treatments. Furthermore, many patients were undertreated; more than 10% of patients did not receive the stan-corticosteroids are first-line therapy for EF, whereas corticosteroids are generally avoided in patients with SSc, given a potential association with renal crisis. Furthermore, visceral involvement in EF is generally limited to hematologic abnormalities, and thus an extensive systemic workup is not indicated as it is in SSc. Clinically, nailfold capillary changes and Raynaud phenomenon are typically absent in EF, unlike in SSc, and skin tightening on the distal digits is lacking. In addition, the groove sign (linear depressions along the course of veins), pseudocellulitic or peau d'orange skin, concurrent plaque morphea, and peripheral eosinophilia may be present in EF. As only 28% of patients in our study had a history of recent trauma or exercise, this criterion may play a more limited role in the etiology and thus diagnosis of EF than traditionally thought. 1, 3 Diagnostic criteria for EF incorporating these characteristics have been recently proposed but remain to be validated. 3 Although corticosteroids remain first-line therapy for EF, their prolonged use in this and 2 other large studies 1,2 demonstrates the need for corticosteroid-sparing therapy. In our study, combination therapy with corticosteroids and methotrexate, which may have corticosteroid-sparing effects, 4,5 portended a higher rate of complete response. Furthermore, our study supports the notion that early treatment of EF results in improved outcomes. 2 This study's limitations include its retrospective nature, the possibility of spontaneous resolution rather than therapeutic effect, and the fact that initial therapeutic intervention occurred at various disease stages, thereby complicating assessment of clinical response. Despite the small sample size, this study represents the largest cohort to date of patients with EF. Further investigation is needed to determine an appropriate treatment algorithm for patients with EF. , imatinib (n = 2), rituximab (n = 2), colchicine (n = 2), extracorporeal photopheresis (n = 2), cyclosporine (n = 2), nonsteroidal anti-inflammatory drugs (n = 2), compression stockings (n = 2), calcipotriol (n = 2), intravenous immunoglobulin (n = 1), azathioprine (n = 1), sulfasalazine (n = 1), penicillamine (n = 1), psoralen UV-A phototherapy (n = 1), clopidogrel (n = 1), triamterene-hydrochlorothiazide (n = 1), clobetasol (n = 1), fluocinolone (n = 1), and halobetasol (n = 1). 
Sexual Orientation and Indoor Tanning Device Use: A Population-Based Study
There is an increasing national focus on addressing the health of lesbian, gay, bisexual, and transgender populations. 1 Emerging evidence suggests that sexual minority populations may face higher burdens of psychosocial and physical health issues, including disparities in cancer-related behavioral risk factors and screening behaviors, compared with heterosexual, cisgender populations. 2, 3 However, there is scant research on the burden of skin cancers and their risk factors among sexual minority individuals. Potential sexual orientation disparities in the use of indoor tanning devices, 4 one of the most preventable risk factors for skin cancers, remain poorly understood. This study compares the prevalence of any use and frequent use of indoor tanning devices among gay or lesbian, bisexual, and straight men and women using a population-based survey.
Methods | A cross-sectional study was performed using the 2013 National Health Interview Survey, 3 a population-based survey representative of the US civilian population. Exempt approval was granted by the Emory University Institutional Review Board. Sexual orientation was self-reported through previously described methods. 3 We restricted analysis to adult respondents who identified with "gay" for male or "lesbian or gay" for female respondents, "bisexual," or "straight, that is, not lesbian or gay."
The survey asked about the frequency of indoor tanning device use within 12 months before the survey, including sunlamps, sun beds, or tanning booths but not spray-on tans. Frequent tanning was defined as 10 or more uses within the 12-month period. Prevalence estimates were weighed to account for the complex survey design to produce nationally representative estimates. Prevalence of indoor tanning among gay or lesbian, bisexual, and straight individuals was compared, with stratification by age and sex, using the Rao-Scott χ 2 test and modeled using multivariate logistic regression (STATA software, version 12.1; StataCorp). Two-sided tests with P < .05 were considered significant.
Results | Among 34 557 survey respondents, 571, 233, and 32 546 individuals identified as gay or lesbian, bisexual, and straight, respectively. Compared with heterosexual counterparts, sexual minority men were younger and had higher educational levels; sexual minority women were younger and had different educational level patterns ( Table 1) . Bisexual women reported higher rates of low income (post hoc P = .002) and no health insurance (post hoc P = .02). No difference in geographic region or skin cancer history was noted.
Significant sexual orientation disparities in indoor tanning were noted among sexual minority men ( Indoor tanning disparities among sexual minority men persisted after adjustment for covariates associated with indoor tanning, including younger age group, higher educational level, non-Hispanic white race, higher income, and Midwest location ( Table 2 ). Younger bisexual women reported lower odds of any tanning (0.4 [0.2-0.8]), but the difference was not observed in multivariate modeling.
Discussion | Novel sexual orientation disparities in indoor tanning among gay and bisexual men, independent of sociodemographic differences, were identified as compared with straight men. These results are consistent with a study of 78 sexual minority and 1689 heterosexual young men aged 16 to 29 years, with sexual minority men reporting a 2.9-fold higher odds of indoor tanning. 4 Larger future studies may increase prevalence estimate reliability among sexual minority populations. Concurrent health risk behaviors, intersectionality with socioeconomic disparities, health care access barriers, stigmatization and minority stress, and other sociocultural contexts should be explored as potential mediators. [1] [2] [3] [4] The roles of body image dissatisfaction and negative appearance evaluation
